IMAB News - Candlesense

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the t...

Board

1 day ago

I-Mab to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for th...

Investor conferences

5 days ago

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents...

How does IMAB's cash runway and capital allocation plan impact its ability to fund upcoming trials and potential dilution risk? What are the key pipeline catalysts and their likelihood of achieving upcoming milestones? How will the Q2 2025 earnings compare to consensus estimates and affect IMAB's valuation?

Earnings

6 days ago